Join us for a stellar panel with contributors from Amplified Sciences, BioCrossroads, Eli Lilly Ventures, and MedTech United. As industry leaders and innovators, our speakers will explore how their combined expertise play into the larger and revolutionizing healthcare landscape.
Our speakers will discuss the challenges and opportunities of integrating health tech into traditional care models, how these innovations are improving patient outcomes, and what the future holds for personalized, tech-driven healthcare. Whether you're a healthcare professional, entrepreneur, investor, or tech enthusiast, this event will provide key insights into how health tech is shaping the future of care and the impact it will have on patient wellness, healthcare delivery, and the broader industry.
Venue: Woodstock Country Club
Meet the Speakers:
Diana Caldwell, Amplified Sciences
Diana is an accomplished and recognized serial life science entrepreneur with over 25 years of experience in both large corporate and small entrepreneurial environments. Throughout her career, she has successfully driven organizational growth, developed and implemented strategic business plans, raised capital, launched novel life science products, and directed successful teams.
Prior to taking helm as CEO of Amplified Sciences, Diana served as an Entrepreneur in Residence at the Purdue Foundry supporting several early-stage startups. Early in her career, she worked for Eli Lilly for over 15 years in a variety of general management leadership roles in product management, marketing, finance, sales, and operations.
In 2010, Diana co-founded Pearl Pathways where she led the company as President and CEO and oversaw all strategic plans and business operations. Pearl Pathways (exit to Versiti CRO in 2023) is a life science product development consulting company focused on expediting regulatory pathways, building and enhancing quality management systems, delivering AHHRPP accredited IRB clinical research review services, and executing clinical trials through a niche CRO offering. Under her leadership she was able to scale the company to a multimillion-dollar company with fifteen employees and dozens of consultant partners.
Vince Wong, BioCrossroads
Vince Wong brings significant valuable multinational and startup company experience to BioCrossroads and the Indiana Seed Fund where he joined as CEO in 2024. With Vince’s leadership, BioCrossroads brings together industry, academia, government, and philanthropy stakeholders to advance Indiana’s life science sector. BioCrossroads is helping enable and fund startups, expand manufacturing, advance workforce development, and drive attraction and retention of life science companies, talent, and capital.
Prior to BioCrossroads, Vince served as chief commercial officer at Geneoscopy, a venture-backed startup focused on developing RNA based gastrointestinal diagnostics. He led the company’s efforts in business development, biopharma partnering, government affairs, market access, marketing, sales and communications. He also helped raise over $100M in venture capital. Prior to Geneoscopy, Vince enjoyed a 17- year career at Roche Diagnostics, where he held senior leadership roles, including leading the $600M Specialty Diagnostics business unit with over 400 team members. Vince serves as a director on the board of Bionano Genomics (Nasdaq: BNGO) and Executive in Residence with IU Ventures.
Vince is an active community leader and has served on the boards of numerous civic and arts organizations, including the Indy Chamber, Dance Kaleidoscope, Asian American Alliance, International Violin Competition of Indianapolis, and the Indianapolis Museum of Art. Vince serves on the boards of the Indiana Biosciences Research Institute and OrthoWorx and board of advisors for Indiana University Indianapolis. Indianapolis Business Journal recognized Vince among both the 40 Under Forty and Indiana 250. Vince earned a BA from the University of Notre Dame, a JD from Indiana University's Maurer School of Law, and an MBA from Northwestern University's Kellogg School of Management.
Beyond traveling internationally, Vince and his family enjoy spending time outdoors, especially hiking, skiing, and mountain biking.
Austin Bruen, Lilly Ventures
Austin Bruen leads therapeutic-focused investment activities at Lilly Ventures, the corporate venture arm of Eli Lilly and Company. Having led dozens of direct and fund investments, Austin has contributed to Lilly Ventures becoming one of the most active early-stage life science investors. Austin also is responsible for the group’s strategy and serves as a member of the investment committee.
Prior to joining Lilly’s venture arm, he held various roles across the organization, including Lilly Research Labs, Treasury, Lilly Japan, and Manufacturing. Austin also spent time working at Lightbank Ventures in Chicago.
Austin received a Master of Business Administration from Kellogg School of Management at Northwestern University. He completed his undergraduate studies at the University of Notre Dame.
Mike Ketcham, MedTech United
Mike is the Founder and President of MedTech United, a vetted private community of founders and executives in the medical technology industry where leaders connect, collaborate, and share insights to drive commercial success.
Before launching MedTech United, Mike was VP of Marketing at Qardio, a leading provider of remote patient monitoring products and services. Prior to that, he founded Staccato Brands, a vertically integrated medical device company. Mike’s experience ranges from startups to Fortune 200 companies, including Eli Lilly and Roche Diagnostics. His expertise spans a range of markets—diagnostics, medical devices, SaaS, and pharmaceuticals—and commercial channels such as DTC/B2C, B2B2C, and B2B.
Mike holds an MBA from the University of Chicago Booth School of Business and a Master of Science in Biochemical Engineering from Purdue University.
He has been actively involved in nonprofit leadership, most recently serving a four-year term as President of the Board of Directors for Westfields Aquatics.